For Sponsors and CROs
The Cardiovascular Site That Hits Your Enrollment Numbers -- and the Diversity Your Reviewers Now Demand
Senior PI is Dr. William W. O'Neill, U.S. TAVR pioneer and National PI on Edwards PARTNER, Protect II, and Protect IV. 20+ pharma sponsors. ICH-GCP E6(R3) compliant. The only dedicated cardiovascular ASC in South Florida sits 12 miles from our front door. Hispanic, Haitian, and Caribbean enrollment baked in -- your FDA Diversity Action Plan, already covered.
Trusted by Alnylam / Pfizer / Pharmacosmos / JK07 Bio / VASA Therapeutics / Cardiovascular Systems / 14 more.
Two outpatient cardiology offices in Miami-Dade plus a dedicated ASC — see locations.
See full trial services →See site capabilities →
Are you a referring physician? See our physician info →
Powered by amavita Heart and Vascular Health® — the largest independent cardiovascular practice in Miami
Sponsors get enrollment from a continuously-recruiting cardiology practice with a high cardiovascular patient volume — not a CRO sourcing from referral networks. Our PIs see trial-eligible patients in clinic every day, screen them in real time, and convert them in the same building.
amavita Heart and Vascular Health® is the largest cardiology practice in Miami owned by a private physician (Dr. Pedro Martinez-Clark, MD, P.A.) — independent of any academic medical system. That ownership structure is the enrollment moat: in-house patient flow no competing Miami site has.
In-house
Continuous CV patient pipeline from the parent practice
No referrals
Eliminates the slow, costly CRO referral-network bottleneck
Same building
Trial conversion happens at the point of cardiology care
Why Amavita
Six reasons sponsors choose Amavita Research as their Miami site partner.
IAOCR GCSA Recertified May 2026
Sponsor audit prep, condensed. GCSA is the only ISO-style site accreditation in clinical research. We were recertified on 13 May 2026 (valid through 28 February 2027). Your monitor does not have to verify what an independent body has already certified. See /certifications for full scope.
ICH-GCP E6 (R3) Compliant
Already operating to E6(R3). When your protocol crosses a regulator's desk, our quality systems are not a question -- they are a footnote.
Blue-Chip Track Record
Trusted by 20+ sponsors including Alnylam, Pfizer, Pharmacosmos, JK07 Bio, and VASA Therapeutics. The same sponsors keep coming back for their second and third study with us -- that is the data point that matters.
Top-5 CV Site, Southeast US
Top-5 cardiovascular site in the Southeast US, by enrollment. The fewer competing sites in your study tier, the more your timeline depends on the ones that perform. We are one of them.
Diverse Miami Population
Hispanic, Haitian, and Caribbean recruitment baked in. With FDA Diversity Action Plans now mandatory for Phase 3 cardiovascular trials, our zip code is a regulatory moat -- not a marketing line.
Dedicated BD Contact
One contact: Nereisy Alonso, Sr CRC. Feasibility, budget, contracts, monitor access -- answered the same business day. No swivel-chair across four people on your CRO call.
A Senior PI with a track record of FDA-pivotal device trial leadership
Our Senior Principal Investigator Dr. William W. O'Neill, MD, FACC has served as National Principal Investigator on the Edwards PARTNER, Protect II, and Protect IV trials — a track record of FDA-pivotal device trial leadership matched by few investigators in the United States.
South Florida's only dedicated cardiovascular ambulatory surgery center
Sponsors partnering with Amavita Research gain access to South Florida's only dedicated cardiovascular ASC — enabling complex device and structural-heart studies, same-day procedures, and a controlled outpatient setting that streamlines protocol execution and reduces hospital-based variability.
ASC Capabilities
Procedures supported on-site
Complex device, structural-heart, and interventional studies executed in a controlled outpatient setting — reducing hospital-based variability.
Cardiology
- Cardiac Catheterization
- Cardiac Mapping & Ablation
- Coronary Intervention
- Implantable Cardiac Monitors
- Pacemakers / ICDs / Bi-Ventricular Devices
- Peripheral Artery & Vein Angiography & Intervention
Interventional Radiology
- Dialysis Access Management
- Genicular / Hemorrhoidal / Prostate Artery Embolization
- Kyphoplasty
- Spinal Cord Stimulator Implantation
- Uterine Fibroid Embolization
Technology
Capabilities that move your study forward
From feasibility through close-out, our team operates as a true extension of yours — bringing deep cardiometabolic experience and the infrastructure to execute complex protocols.
Therapeutic Expertise
Deep experience across cardiology, heart failure (HFrEF/HFpEF), hypertension, ACS, vascular and metabolic studies — Phase 1 through Phase 3.
Modern Recruitment Technology
EHR-integrated patient identification, predictive screening, and a digital pre-screening funnel that accelerates enrollment.
Trained, Bilingual Staff
Board-certified PI, study coordinators, and regulatory specialists fluent in English, Spanish, and Haitian Creole — matching South Florida's patient population.
Miami-Area Patient Diversity
Access to one of the most ethnically and clinically diverse patient populations in the United States.
Trusted by leading sponsors
- Janssen
- Pfizer
- Alnylam Pharmaceuticals
- Duke Clinical Research Institute
- Pharmacosmos
- Cardurion Pharmaceuticals
- River 2 Renal
- Novo Nordisk
- Boehringer Ingelheim
- Novartis
- GE Healthcare
- AngioDynamics
- Avantec Vascular
- Vir Biotechnology / GSK
- Revive Therapeutics
- CSL Behring
- Cordio Medical
- ImpediMed
- Vifor Pharma
- Salubris Biotherapeutics (JK07 Bio)
20+ pharmaceutical, biotech, and device partners — across active and completed trials
Track Record - Numbers, Not Adjectives
Performance you can underwrite
Anonymized site-level operational metrics from a 2024-active interventional vascular trial. Specific protocol disclosed under CDA.
41 days
CTA → First Patient In
Recent device atherectomy trial, 2024
32 of 39
Enrolled, on track to be first to cap
Site enrollment cap; pace-leading the trial
High retention
Through 30-day primary endpoint
Freedom from major adverse events
2–4 wk
IRB submission turnaround
Across active 2024-2025 trials
Per-protocol enrollment, screen-fail rate, and timeline data available under mutual CDA.
Sponsor Relationships
Julio G. Martinez-Clark
Chief Executive Officer (CEO)
Schedule a Sponsor ConsultationOperations & Study Coordination
Nereisy Alonso, Sr CRC
Chief Operations Officer
Questions about how we work?
14 direct answers on PIs, timelines, capacity, certifications, cost, data ownership, and more.
FAQ
Frequently Asked Questions
Quick answers about our certifications, leadership, and sponsor partnerships.